Viatris Inc. (VTRS): Price and Financial Metrics
VTRS Price/Volume Stats
| Current price | $11.56 | 52-week high | $12.49 |
| Prev. close | $11.74 | 52-week low | $8.74 |
| Day low | $11.44 | Volume | 6,830,100 |
| Day high | $11.70 | Avg. volume | 9,666,812 |
| 50-day MA | $10.95 | Dividend yield | 4.15% |
| 200-day MA | $10.11 | Market Cap | 13.87B |
VTRS Stock Price Chart Interactive Chart >
VTRS POWR Grades
- VTRS scores best on the Value dimension, with a Value rank ahead of 99.03% of US stocks.
- The strongest trend for VTRS is in Stability, which has been heading up over the past 26 weeks.
- VTRS ranks lowest in Momentum; there it ranks in the 6th percentile.
VTRS Stock Summary
- VTRS's went public 36.07 years ago, making it older than 90.81% of listed US stocks we're tracking.
- VTRS's current price/earnings ratio is 7.45, which is higher than only 10.93% of US stocks with positive earnings.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VTRS comes in at 20.34% -- higher than that of 91.81% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to VIATRIS INC, a group of peers worth examining would be CW, BAX, OC, PLPC, and PNR.
- Visit VTRS's SEC page to see the company's official filings. To visit the company's web site, go to www.viatris.com.
VTRS Valuation Summary
- In comparison to the median Healthcare stock, VTRS's price/sales ratio is 80.95% lower, now standing at 0.8.
- Over the past 243 months, VTRS's price/sales ratio has gone down 4.
Below are key valuation metrics over time for VTRS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VTRS | 2023-12-29 | 0.8 | 0.6 | 7.1 | 9.7 |
| VTRS | 2023-12-28 | 0.8 | 0.6 | 7.1 | 9.7 |
| VTRS | 2023-12-27 | 0.8 | 0.6 | 7.1 | 9.7 |
| VTRS | 2023-12-26 | 0.8 | 0.6 | 7.0 | 9.6 |
| VTRS | 2023-12-22 | 0.8 | 0.6 | 7.0 | 9.6 |
| VTRS | 2023-12-21 | 0.8 | 0.6 | 7.0 | 9.6 |
VTRS Growth Metrics
- Its 5 year net cashflow from operations growth rate is now at -11.78%.
- The 4 year cash and equivalents growth rate now stands at -20.92%.
- Its 4 year price growth rate is now at -55.64%.
The table below shows VTRS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 16,728.3 | 3,333.1 | 803.6 |
| 2022-06-30 | 17,186.7 | 3,549.7 | 760.8 |
| 2022-03-31 | 17,647.7 | 3,306.6 | 167.7 |
| 2021-12-31 | 17,886.3 | 3,016.9 | -1,269.1 |
| 2021-09-30 | 17,168.2 | 2,530 | -1,921.1 |
| 2021-06-30 | 15,603.7 | 1,969.4 | -2,046.9 |
VTRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VTRS has a Quality Grade of D, ranking ahead of 8.02% of graded US stocks.
- VTRS's asset turnover comes in at 0.298 -- ranking 155th of 682 Pharmaceutical Products stocks.
- CRIS, KDNY, and AGIO are the stocks whose asset turnover ratios are most correlated with VTRS.
The table below shows VTRS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.298 | 0.277 | -0.030 |
| 2021-03-31 | 0.302 | 0.292 | -0.027 |
| 2020-12-31 | 0.312 | 0.318 | -0.011 |
| 2020-09-30 | 0.375 | 0.363 | 0.058 |
| 2020-06-30 | 0.375 | 0.356 | 0.052 |
| 2020-03-31 | 0.374 | 0.344 | 0.047 |
VTRS Price Target
For more insight on analysts targets of VTRS, see our VTRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.21 | Average Broker Recommendation | 1.72 (Moderate Buy) |
Viatris Inc. (VTRS) Company Bio
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn, a division of Pfizer, on November 16, 2020. (Source:Wikipedia)
Latest VTRS News From Around the Web
Below are the latest news stories about VIATRIS INC that investors may wish to consider to help them evaluate VTRS as an investment opportunity.
Regeneron Gains After Eye-Drug Patent Victory Over Viatris(Bloomberg) -- Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc. Most Read from BloombergThe Late-Night Email to Tim Cook That Set the Apple Watch Saga in MotionChinese Carmaker Overtakes Tesla as World’s Most Popular EV MakerBridgewater CEO’s Past Office Romance Led to Favoritism ClaimsXiaomi Unveils Its First EV, With Ambition to Be China’s Porsche o |
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceViatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024. Chief Executive Officer Scott A. Smith, President Rajiv Malik and Chief Financial Officer Sanjeev Narula will represent the company in a presentation followed by a fireside chat scheduled at 10:30 a.m. PST / 1:30 p.m. ET. |
Why Investors Need to Take Advantage of These 2 Medical Stocks NowInvestors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. |
UPDATE 1-Drugmaker Viatris appoints Theodora Mistras as CFOGlobal healthcare company Viatris on Friday appointed Theodora Mistras as its chief financial officer, effective March 1. The company said the current CFO Sanjeev Narula will work closely with Mistras to support a smooth transition and will then depart the company on March 1. Mistras most recently was the managing director of healthcare investment banking at Citigroup Global Markets and has almost two decades of leadership, advisory and capital markets experience, Viatris said. |
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D OfficerViatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial Officer (CFO) effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect. |
VTRS Price Returns
| 1-mo | -0.34% |
| 3-mo | 27.28% |
| 6-mo | 4.29% |
| 1-year | 1.72% |
| 3-year | -28.18% |
| 5-year | N/A |
| YTD | 6.74% |
| 2023 | 2.06% |
| 2022 | -14.29% |
| 2021 | -26.12% |
| 2020 | N/A |
| 2019 | N/A |
VTRS Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...